• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner

    7/2/24 8:00:00 AM ET
    $NXPL
    $OPK
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NXPL alert in real time by email

    New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additional E-Commerce Platforms, in Brick-and-Mortar Retail Locations and Launch In-Country Digital Marketing Programs

    COCONUT GROVE, Fla., July 2, 2024 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW))) ("NextPlat" or the "Company"), a global e-Commerce provider, today announced that it has expanded its e-commerce development program in China through a new agreement with a leading Chinese healthcare and nutritional products marketing and distribution services partner (the "Marketing Partner"). The Marketing Partner will provide NextPlat with a full range of creative content, brand marketing and product sales and distribution services and support the Company's exclusive joint e-commerce development agreement with OPKO Health Europe ("OPKO"), a subsidiary of OPKO Health, Inc. (NASDAQ:OPK).

    NextPlat Corp. logo (PRNewsfoto/NextPlat Corp.)

    As a marketing specialist in China, the Marketing Partner currently supports international healthcare and nutritional products companies including Nature Made and ITO, and provides logistics, warehousing and distribution services throughout China. The Marketing Partner has successfully developed and executed brand awareness campaigns for healthcare products on dozens of e-commerce sites such as Alibaba's Tmall, JD and Temu, and on digital/social platforms such as TikTok, Xiaohongshu, Weibo, Bilibili and WeChat. The Marketing Partner also supports product distribution into physical stores such as pharmacies, convenience stores and supermarkets, as well as into major U.S.-based retail chains operating in China including Costco and Sam's Club. The Marketing Partner is developing a series of digital product promotion programs for select OPKO products which are expected to contribute to NextPlat's Chinese e-commerce sales later this year. These marketing programs may include utilizing well-known Chinese social media influencers, live videos/broadcasts on social media platforms, and articles and product blogs designed to introduce OPKO products to potentially millions of consumers.

    "Our unique e-commerce development program was created to provide American companies with turn-key online sales, marketing and distribution access into the large Chinese consumer market without requiring the significant international infrastructure investments typically required. Through the addition of well-established marketing specialists in China, we believe we can provide our clients with a greater array of value-added services which can help drive product awareness and revenue," said Charles M. Fernandez, Executive Chairman and CEO of NextPlat.

    According to TMO Group (Health & Food Supplements, China Market, April 2024), China, with its rapidly growing middle class, shows increasing interest in lifestyle and many non-prescription health options with increases in income levels supporting an emphasis on health and wellness. The report cites data from Euromonitor International, showing that over the past five years, the health supplement market (including vitamins and dietary supplements (VDS), sports nutrition, weight management and wellbeing, and herbal/traditional supplements) in China has steadily increased, reaching approximately 387.9 billion RMB (approximately $53.3 billion) in 2023, with a compound annual growth rate of 9.6%. It is expected that by 2028, the health supplements market in China will exceed 440 billion RMB (approximately $60.5 billion). The TMO Group report also indicates that the online channel is the most important channel for VDS products, especially for cross-border imported products and that in 2023, health supplements from the U.S. and Australia were the first choices for Chinese consumers.

    "Today's new healthcare products marketing partnership in China broadens our digital and physical reach, including potentially dozens of additional online platforms as well as brick-and-mortar retailers across the country. Importantly, we can offer a valuable array of digital and social media promotion capabilities provided by a partner who has built a strong client portfolio in China, allowing us to significantly enhance the marketing of our initial OPKO products," said David Phipps, President of NextPlat and CEO of Global Operations.

    NextPlat's e-commerce development program, held in coordination with local Florida chambers of commerce, initially aims to help Florida-based businesses and manufacturers market and sell their products to potentially millions of new customers. The development program features NextPlat's turnkey global e-commerce solution and leverages the capabilities and reach of key partners including Alibaba and its Tmall Global platform, and additional in-country marketing and distribution specialists who support cross-border solutions enabling global brands to reach Chinese consumers.

    For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook and X.

    About NextPlat Corp

    NextPlat is a global e-commerce platform company created to capitalize on multiple high-growth sectors and markets including technology and healthcare. Through acquisitions, joint ventures and collaborations, the Company intends to assist businesses in selling their goods online, domestically, and internationally, allowing customers and partners to optimize their e-commerce presence and revenue. NextPlat currently operates an e-commerce communications division offering voice, data, tracking, and IoT products and services worldwide and pharmacy and healthcare data management services in the United States through its subsidiary, Progressive Care Inc. (OTCQB:RXMD).

    Forward-Looking Statements

    Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to launch additional e-commerce platforms, sell healthcare products in China, and its ability to grow and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

    No Offer or Solicitation

    This press release is for informational purposes only and is not intended to and shall not constitute an offer to sell or the solicitation of an offer to sell or to buy any securities or a solicitation of any proxy, consent, vote or approval with respect to any securities in respect of the proposed transaction between NextPlat and Progressive Care Inc. ("Progressive Care") and is not a substitute for the Proxy Statement/Prospectus or any other document that NextPlat or Progressive Care may file with the SEC or send to NextPlat's or Progressive Care's stockholders in connection with the proposed transaction. No offer, sale, issuance or transfer of securities shall be made in any jurisdiction in which such offer, sale, issuance or transfer would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. 

    Media and Investor Contact for NextPlat Corp:

    Michael Glickman

    MWGCO, Inc.

    917-397-2272

    [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplat-expands-e-commerce-program-in-china-to-include-broad-retail-distribution-and-adds-digitalsocial-media-marketing-capabilities-with-new-marketing-partner-302187700.html

    SOURCE NextPlat Corp.

    Get the next $NXPL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXPL
    $OPK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    11/20/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    10/31/2025$1.60Buy → Hold
    Jefferies
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    6/29/2023$2.00Mkt Perform → Outperform
    Barrington Research
    OPKO Health Inc.
    $OPK
    12/15/2022$3.00Buy
    H.C. Wainwright
    OPKO Health Inc.
    $OPK
    1/24/2022Outperform → Market Perform
    Barrington Research
    More analyst ratings

    $NXPL
    $OPK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

    MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    2/12/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism

    This is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; oral OXM to enter clinic thereafter Industry veteran Steve Rubin joins Entera's board MIAMI and TEL AVIV, Israel, Feb. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), through its wholly owned subsidiary, OPKO Biologics (OPKO

    2/4/26 8:00:00 AM ET
    $ENTX
    $OPK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference

    MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco.  Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time. The fireside chat will be webcast live and available for replay in the Investors section of OPKO Health's website here. About OPKO Health OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large,

    1/6/26 4:11:42 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Barreto Rodney was granted 21,176 shares, increasing direct ownership by 5% to 445,585 units (SEC Form 4)

    4 - NextPlat Corp (0001058307) (Issuer)

    1/6/26 4:32:15 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Director Armas Anthony was granted 10,588 shares (SEC Form 4)

    4 - NextPlat Corp (0001058307) (Issuer)

    1/6/26 4:28:57 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Director Ellenoff Douglas was granted 21,176 shares, increasing direct ownership by 15% to 166,176 units (SEC Form 4)

    4 - NextPlat Corp (0001058307) (Issuer)

    1/6/26 4:24:49 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    SEC Filings

    View All

    SEC Form S-8 filed by NextPlat Corp

    S-8 - NextPlat Corp (0001058307) (Filer)

    1/30/26 4:49:02 PM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    Amendment: NextPlat Corp filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K/A - NextPlat Corp (0001058307) (Filer)

    1/13/26 9:05:50 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    SEC Form EFFECT filed by NextPlat Corp

    EFFECT - NextPlat Corp (0001058307) (Filer)

    1/9/26 12:15:12 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Opko Health downgraded by Jefferies with a new price target

    Jefferies downgraded Opko Health from Buy to Hold and set a new price target of $1.60

    10/31/25 8:18:38 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    4/25/25 8:32:28 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Financials

    Live finance-specific insights

    View All

    OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26

    MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    2/12/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NextPlat Reports Third Quarter 2025 Results

    Company Reports $13.8M in Q3 Revenue as Refocusing and Cost Cutting Initiatives Drive Improved Late Quarter Performance with Accelerated Sequential Improvements Expected in Q4 and into 2026  HALLANDALE BEACH, Fla., Nov. 13, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced the financial results for the quarter-ended September 30, 2025, reflecting the performance of its e-Commerce and Healthcare Operations.

    11/13/25 8:03:00 AM ET
    $BABA
    $NXPL
    $OPK
    Real Estate
    Telecommunications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations

    NextPlat to Release Third Quarter 2025 Results on Thursday, November 13, 2025

    Investor Conference Call Scheduled for Thursday, November 13, 2025 at 8:30 a.m. Eastern HALLANDALE BEACH, Fla., Nov. 3, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW)) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that it will release its financial results for the quarter ended September 30, 2025 before market open on November 13, 2025. NextPlat's CEO, President and CEO of Global Operations, David Phipps, its Chief Financial

    11/3/25 8:03:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    $NXPL
    $OPK
    Leadership Updates

    Live Leadership Updates

    View All

    NextPlat Appoints Rodney Barreto as Chairman of the Board and David Phipps as Chief Executive Officer to Lead Ongoing Business Refocusing Efforts

    Company Executes on Initiatives Including New Business Development, Corporate Reinvestment and Implements Additional Cost-Cutting Initiatives HALLANDALE BEACH, Fla., Sept. 9, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-Commerce and retail channels worldwide, today announced that as part of the Company's ongoing business refocusing plans, it has named Rodney Barreto as its permanent Chairman of the Board and David Phipps as its permanent Chief Executive Officer. Messrs. Barreto and Phipps were both serving in interim roles following the pas

    9/9/25 8:01:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    NextPlat Accelerates Healthcare Growth with New Leadership and Expanded Sales, Marketing, and Technology Investments

    Veteran Healthcare Leadership to Drive Business Process Improvement, Enhanced Customer Service and Support the Introduction of New Services for 340B and Long-term Care Providers COCONUT GROVE, Fla., Aug. 26, 2025 /PRNewswire/ -- NextPlat Corp (NASDAQ:NXPL, NXPLW), NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through eCommerce and retail channels worldwide, today announced the strategic expansion of its healthcare operations. This expansion includes a series of developments highlighted by the appointment of new senior leadership and investment into its healthcare operations designed to support its growth in

    8/26/25 8:02:00 AM ET
    $NXPL
    Telecommunications Equipment
    Telecommunications

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NXPL
    $OPK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care